- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
23 result(s) found for: Digestive enzyme.
Displaying page 1 of 2.
EudraCT Number: 2015-005491-20 | Sponsor Protocol Number: 20151205 | Start Date*: 2016-08-29 |
Sponsor Name:Actavis Hungary Gyógyszermarketing és Kereskedelmi Korlátolt Felelősségű Társaság | ||
Full Title: The effect of pancreatic enzyme replacement therapy on glucose metabolism, nutritional parameters, incretin response and beta-cell function in patients with diabetes mellitus and exocrine pancreati... | ||
Medical condition: To study the patients with diabetes mellitus (type 1, 2 and 3c) and exocrine pancreatic insufficiency. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001638-84 | Sponsor Protocol Number: 16-07 | Start Date*: 2016-07-08 |
Sponsor Name:Meander Medical Center | ||
Full Title: Thiopurines with Low Dose Allopurinol: a prospective one way cross-over study | ||
Medical condition: Crohn's disease & Colitis Ulcerosa | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002748-10 | Sponsor Protocol Number: AD-02-013 | Start Date*: 2013-12-12 |
Sponsor Name:Fundación para la Investigación en Enfermedades del Aparato Digestivo | ||
Full Title: A double-blind, randomized, multicenter, placebo-controlled, parallel-group phase IV clinical trial to assess the efficacy of pancreatic enzyme replacement therapy (PERT) in patients with pancreati... | ||
Medical condition: Patients with pancreatic exocrine insufficiency (PEI) secondary to type 1 diabetes mellitus (DM) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-005310-35 | Sponsor Protocol Number: AD-03-013 | Start Date*: 2014-08-13 |
Sponsor Name:Fundación para la Investigación en Enfermedades del Aparato Digestivo | ||
Full Title: A phase IV double-blind, randomized, placebo-controlled, multi-center study with pancreatic enzyme replacement therapy (PERT) in subjects suffering from pancreatic exocrine insufficiency (PEI) afte... | ||
Medical condition: Patients 2 weeks after discharge from the hospital after an attack of acute necrotizing pancreatitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002570-20 | Sponsor Protocol Number: AD-05-013 | Start Date*: 2016-02-25 |
Sponsor Name:Department of gastroenterology. University Hospital of Santiago | ||
Full Title: Open label, randomized, crossover clinical trial to evaluate the efficacy of increasing doses of pancreatic enzymes against inhibition of acid gastric secretion in patients with exocrine pancreatic... | ||
Medical condition: Patients diagnosed of chronic pancreatitis with pancreatic exocrine insufficiency under pancreatic enzyme replacement therapy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005874-24 | Sponsor Protocol Number: PEI004/2021 | Start Date*: 2022-07-01 |
Sponsor Name:Juan Enrique Domínguez Muñoz | ||
Full Title: Open label randomized, multicentre, controlled trial of pancreatic enzyme replacement therapy (PERT) for pancreatic exocrine insufficiency (PEI) in patients with unresectable pancreatic cancer | ||
Medical condition: pancreatic exocrine insufficiency (PEI) in patients with unresectable pancreatic cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001772-37 | Sponsor Protocol Number: FFCD 0604 | Start Date*: 2007-07-12 |
Sponsor Name:Fédération Francophone de Cancérologie Digestive - FFCD | ||
Full Title: Essai de phase II, multicentrique, évaluant le G-CSF en prophylaxie primaire associé au schéma de chimiothérapie FOLFIRI + bévacizumab en 1ère ligne dans le cancer colorectal métastatique chez des ... | ||
Medical condition: Traitement en 1ère ligne dans le cancer colorectal métastatique chez des patients, homozygotes pour le polymorphisme UGT1A1*28 du promoteur du gène codant pour l’enzyme UGT1A1 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-012842-21 | Sponsor Protocol Number: PR-005 | Start Date*: 2010-09-20 | ||||||||||||||||
Sponsor Name:Aptalis Pharma US Inc. | ||||||||||||||||||
Full Title: Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in theTreatment of Exocrine Pancreatic Insufficien... | ||||||||||||||||||
Medical condition: Exocrine pancreatic insufficiency associated with cystic fibrosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) IT (Completed) BG (Completed) BE (Completed) HU (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000537-24 | Sponsor Protocol Number: IIS-HEPA-TEST | Start Date*: 2014-07-16 |
Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA LA FE | ||
Full Title: Pilot clinical trial phase I / IIa to determine condition, low dose and effectiveness of liver function tests (Hepatotest) | ||
Medical condition: Hepatic Function. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002996-91 | Sponsor Protocol Number: CB8025-21629 | Start Date*: 2017-02-21 | |||||||||||
Sponsor Name:CymaBay Therapeutics, Inc. | |||||||||||||
Full Title: An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an in... | |||||||||||||
Medical condition: Primary Biliary Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002182-29 | Sponsor Protocol Number: B1791089 | Start Date*: 2016-06-09 |
Sponsor Name:Pfizer Inc. | ||
Full Title: An Open-Label, Multicenter Study To Evaluate The Pharmacokinetics Of Single And Multiple Intravenous Doses Of Pantoprazole In Two Age Cohorts Of Hospitalized Pediatric Subjects 1 To 16 Years Of Age... | ||
Medical condition: Gastroesophageal Reflux Disease (GERD) | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) DE (Completed) IT (Completed) SK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004141-24 | Sponsor Protocol Number: 228763 | Start Date*: 2018-01-26 | ||||||||||||||||
Sponsor Name:Brighton and Sussex University Hospitals NHS Trus | ||||||||||||||||||
Full Title: A phase IV, open-label pilot study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised backgro... | ||||||||||||||||||
Medical condition: Non-alcoholic fatty liver disease in people living with well-controlled HIV-1 infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001834-20 | Sponsor Protocol Number: APHP191105 | Start Date*: 2021-12-10 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | |||||||||||||
Full Title: Randomized controlled trial testing the efficacy of hydroxychloroquine combined with low dose corticosteroid therapy in pulmonary sarcoidosis | |||||||||||||
Medical condition: mediastino-pulmonary sarcoidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001051-12 | Sponsor Protocol Number: 1708213 | Start Date*: 2018-09-07 | ||||||||||||||||
Sponsor Name:CHU Saint-Etienne | ||||||||||||||||||
Full Title: VEDO - PREDIRESPUC project - Value of pharmacokinetic assays (Vedolizumab and anti-vedolizumab antibody) in the prediction of induction and maintenance therapeutic response in Ulcerative Colitis | ||||||||||||||||||
Medical condition: Ulcerative Colitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002526-25 | Sponsor Protocol Number: EP-547-201 | Start Date*: 2022-11-30 | |||||||||||
Sponsor Name:Escient Pharmaceuticals, Inc. | |||||||||||||
Full Title: Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP547 in Subjects with Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis | |||||||||||||
Medical condition: Subjects with Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001634-10 | Sponsor Protocol Number: SARO.21.001 | Start Date*: 2023-01-23 | |||||||||||
Sponsor Name:Zydus Therapeutics Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects with Primary Biliary Cholangitis. | |||||||||||||
Medical condition: Primary biliary Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IS (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001171-20 | Sponsor Protocol Number: CB8025-31735 | Start Date*: 2018-11-23 |
Sponsor Name:CymaBay Therapeutics, Inc. | ||
Full Title: A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intole... | ||
Medical condition: Primary biliary cholangitis (PBC, formerly known as primary biliary cirrhosis) is a serious and potentially life threatening autoimmune disease of the liver characterized by impaired bile flow (cho... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Temporarily Halted) HU (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) BE (Completed) IT (Prematurely Ended) RO (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-023909-35 | Sponsor Protocol Number: BVT.BSSL-030 | Start Date*: 2011-06-24 | |||||||||||
Sponsor Name:Swedish Orphan Biovitrum AB (publ) | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Phase 3 Study Comparing rhBSSL and Placebo Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants Born Before Wee... | |||||||||||||
Medical condition: Prevention of growth retardation due to lack of bile salt-stimulated lipase in enteral nutrition | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) HU (Completed) FR (Ongoing) CZ (Completed) PL (Prematurely Ended) ES (Prematurely Ended) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000007-21 | Sponsor Protocol Number: 212620 | Start Date*: 2021-08-16 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||||||||||||||||||
Full Title: A two-part, randomized, placebo controlled, double blind, multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants wit... | ||||||||||||||||||
Medical condition: Moderate to severe Cholestatic pruritus with primary biliary cholangitis (PBC). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) BE (Completed) IT (Completed) CZ (Completed) GR (Completed) ES (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020484-20 | Sponsor Protocol Number: 20621-200 | Start Date*: 2011-07-05 | |||||||||||
Sponsor Name:ViroPharma Incorporated | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF VP 20621 FOR PREVENTION OF RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) IN AD... | |||||||||||||
Medical condition: Clostridium difficile infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
